Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Biagio Ricciuti, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Nishino M, Hatabu H, Ricciuti B, Vaz V, Michael K, Awad MM. Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. J Thorac Oncol. 2021 Sep 28. PMID: 34506955.
    Citations:    Fields:    
  2. Wang X, Ricciuti B, Alessi JV, Nguyen T, Awad MM, Lin X, Johnson BE, Christiani DC. Response to Hopkins, Kichenadasse, Logan, et al. J Natl Cancer Inst. 2021 Aug 27. PMID: 34450659.
    Citations:    Fields:    
  3. Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021 Aug 13. PMID: 34400292.
    Citations:    Fields:    
  4. Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. J Thorac Oncol. 2021 07; 16(7):1176-1187. PMID: 33845210.
    Citations: 2     Fields:    Translation:Humans
  5. Baglivo S, Bianconi F, Metro G, Gili A, Tofanetti FR, Bellezza G, Ricciuti B, Mandarano M, Teti V, Siggillino A, Reda MS, Chiari R, Pistola L, Sidoni A, Minotti V, Roila F, Ludovini V. Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes (Basel). 2021 06 29; 12(7). PMID: 34209514.
    Citations:    Fields:    
  6. Wang X, Ricciuti B, Alessi JV, Nguyen T, Awad MM, Lin X, Johnson BE, Christiani DC. Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2021 Jun 11. PMID: 34115098.
    Citations:    Fields:    
  7. Bassanelli M, Ricciuti B, Giannarelli D, Cecere FL, Roberto M, Giacinti S, Barucca V, Santarelli M, Ruggeri EM, Marchetti P, Cognetti F, Gelibter A, Cortesi E, Chiari R, Milella M, Ceribelli A. Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. Tumori. 2021 Apr 04; 3008916211004733. PMID: 33818208.
    Citations:    Fields:    
  8. Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, Nagano T, Legras A, Breadner D, Ricciuti B, Divisi D, Schmid RA, Peng RW, Yang H, Yao F. Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. Transl Lung Cancer Res. 2021 Apr; 10(4):1857-1872. PMID: 34012798.
    Citations:    
  9. Vora KB, Ricciuti B, Awad MM. Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. Sci Rep. 2021 03 23; 11(1):6637. PMID: 33758321.
    Citations:    Fields:    
  10. Nishino M, Hong F, Ricciuti B, Hatabu H, Awad MM. Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 5. PMID: 34250409.
    Citations:    
  11. Wang X, Ricciuti B, Nguyen T, Li X, Rabin MS, Awad MM, Lin X, Johnson BE, Christiani DC. Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. Cancer Res. 2021 05 01; 81(9):2566-2573. PMID: 33653773.
    Citations: 4     Fields:    Translation:Humans
  12. Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021 03; 9(3). PMID: 33771889.
    Citations: 2     Fields:    
  13. Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol. 2020 12 01; 6(12):1952-1956. PMID: 33119034.
    Citations: 16     Fields:    Translation:Humans
  14. Xie T, Li Y, Ying J, Cai W, Li J, Lee KY, Ricciuti B, Pacheco J, Xing P. Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). Transl Lung Cancer Res. 2020 Dec; 9(6):2428-2439. PMID: 33489804.
    Citations:    
  15. Ricciuti B, Awad MM. Reply to Cortellini A. JTO Clin Res Rep. 2020 Nov; 1(4):100095. PMID: 34589967.
    Citations:    
  16. Ricciuti B, Awad MM. What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer? Cancer J. 2020 Nov/Dec; 26(6):485-495. PMID: 33298719.
    Citations: 2     Fields:    Translation:Humans
  17. Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, Catino A, Passiglia F, Torniai M, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Rastelli F, Chiari R, Rocco D, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Grossi F, Filetti M, Pizzutilo P, Russano M, Citarella F, Cantini L, Targato G, Nigro O, Ferrara MG, Buti S, Scodes S, Landi L, Guaitoli G, Della Gravara L, Tabbò F, Ricciardi S, De Toma A, Friedlaender A, Petrelli F, Addeo A, Porzio G, Ficorella C. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression = 50%: a multicenter study with external validation. J Immunother Cancer. 2020 10; 8(2). PMID: 33077515.
    Citations: 14     Fields:    Translation:Humans
  18. Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A, Paweletz C, Supplee J, Jänne PA, Severgnini M, Awad MM, Walt DR. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020 10; 8(2). PMID: 33020238.
    Citations: 8     Fields:    Translation:Humans
  19. Park H, Hatabu H, Ricciuti B, Aijazi SJ, Awad MM, Nishino M. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol. 2020 Nov; 132:109275. PMID: 32949913.
    Citations: 2     Fields:    Translation:Humans
  20. Alessi JV, Ricciuti B, Jiménez-Aguilar E, Hong F, Wei Z, Nishino M, Plodkowski AJ, Sawan P, Luo J, Rizvi H, Carter BW, Heymach JV, Altan M, Hellmann M, Awad M. Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2). PMID: 32753547.
    Citations: 6     Fields:    Translation:Humans
  21. Ricciuti B, Naqash AR, Naidoo J, Sehgal K, Miller A, Kehl K, Venkatraman D, Sands J, Lamberti G, Recondo G, Zhang J, Macherla S, Baig S, Walker P, Rangachari D, Gainor JF, Costa DB, Rizvi N, Sholl LM, Nishino M, Henick B, Farago AF, Awad MM. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100074. PMID: 34589955.
    Citations:    
  22. Cravero P, Vaz N, Ricciuti B, Clifford SE, DiUbaldi G, Drevers D, Morton K, Rivenburgh RE, Nishino M, Awad MM. Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100072. PMID: 34589954.
    Citations:    
  23. Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020 07; 69(7):1189. PMID: 32347358.
    Citations: 1     Fields:    
  24. Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression = 50% and Their Relationship With Clinical Outcomes. Clin Lung Cancer. 2020 11; 21(6):498-508.e2. PMID: 32680806.
    Citations: 16     Fields:    
  25. Lamberti G, Andrini E, Sisi M, Federico AD, Ricciuti B. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Future Oncol. 2020 Aug; 16(23):1751-1766. PMID: 32539551.
    Citations: 6     Fields:    Translation:HumansCells
  26. Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of =?50. Cancer Immunol Immunother. 2020 Nov; 69(11):2209-2221. PMID: 32474768.
    Citations: 12     Fields:    Translation:Humans
  27. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. Eur J Cancer. 2020 07; 134:19-28. PMID: 32454395.
    Citations: 6     Fields:    Translation:Humans
  28. Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 06; 31(6):807-814. PMID: 32171752.
    Citations: 13     Fields:    Translation:Humans
  29. Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4135-4142. PMID: 32332016.
    Citations: 12     Fields:    
  30. De Giglio A, Lamberti G, Facchinetti F, Genova C, Andrini E, Dal Bello MG, Tiseo M, Metro G, Chiari R, Ricciuti B. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. Clin Lung Cancer. 2020 09; 21(5):e478-e487. PMID: 32409267.
    Citations:    Fields:    
  31. Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020 Jul; 69(7):1177-1187. PMID: 32140762.
    Citations: 20     Fields:    Translation:Humans
  32. Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020 03; 128:17-26. PMID: 32109847.
    Citations: 16     Fields:    Translation:Humans
  33. Pertejo-Fernandez A, Ricciuti B, Hammond SP, Marty FM, Recondo G, Rangachari D, Costa DB, Awad MM. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer. 2020 07; 145:181-185. PMID: 32423643.
    Citations: 9     Fields:    Translation:Humans
  34. Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, Cherniack AD, Price KS, Fairclough SR, Nishino M, Sholl LM, Oxnard GR, Jänne PA, Awad MM. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020 06 01; 26(11):2615-2625. PMID: 32034073.
    Citations: 21     Fields:    Translation:Humans
  35. Ricciuti B, Lamberti G, Andrini E, Genova C, De Giglio A, Bianconi V, Sahebkar A, Chiari R, Pirro M. Antibody-drug conjugates for lung cancer in the era of personalized oncology. Semin Cancer Biol. 2021 Feb; 69:268-278. PMID: 31899248.
    Citations: 1     Fields:    
  36. Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer. 2020 02; 140:59-64. PMID: 31881412.
    Citations: 9     Fields:    Translation:Humans
  37. Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411. PMID: 32067682.
    Citations: 15     Fields:    Translation:Humans
  38. Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 02 20; 38(6):576-583. PMID: 31800340.
    Citations: 28     Fields:    Translation:Humans
  39. Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, Fu X, Gao S, Hu J, Huang Y, Jiang G, Jiao W, Li S, Li G, Li H, Li H, Li X, Liang N, Liu D, Liu H, Liu J, Liu L, Liu Y, Luo Q, Ma H, Mao W, Peng Z, Qiao G, Shao G, Tan L, Tan Q, Wang Q, Wang C, Wu Q, Xu S, Xu S, Xu L, Yang Y, Yu F, Zhang B, Zhang L, Zhao B, Zhi X, Brunelli A, Petersen RH, Liu CC, Ricciuti B, Metro G, Tuzi A, Suter MB, Evison M, Seki N, Sasada S, Izumo T, Cho WC, He J. Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Transl Lung Cancer Res. 2019 Dec; 8(6):1163-1173. PMID: 32010594.
    Citations: 21     
  40. Ricciuti B, Lamberti G, Roila F, Metro G. Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option. Transl Lung Cancer Res. 2019 Dec; 8(Suppl 4):S378-S382. PMID: 32038919.
    Citations:    
  41. Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3. PMID: 31832578.
    Citations: 13     
  42. Abu-Sbeih H, Ali FS, Owen DH, Ricciuti B, Naqash AR, Wang Y. Reply to J. Delyon et al. J Clin Oncol. 2019 12 20; 37(36):3564-3565. PMID: 31596634.
    Citations:    Fields:    Translation:Humans
  43. Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659. PMID: 31435660.
    Citations: 45     Fields:    Translation:Humans
  44. Lamberti G, Andrini E, Ricciuti B. Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. J Thorac Dis. 2019 Sep; 11(Suppl 15):S1831-S1834. PMID: 31632761.
    Citations: 1     
  45. Ricciuti B, Leonardi GC, Brambilla M. Emerging Biomarkers in the Era of Personalized Cancer Medicine. Dis Markers. 2019; 2019:5907238. PMID: 31485277.
    Citations:    Fields:    Translation:Humans
  46. Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. Clin Transl Oncol. 2020 Jun; 22(6):844-851. PMID: 31392645.
    Citations: 3     Fields:    Translation:Humans
  47. Ricciuti B, Brambilla M, Cortellini A, De Giglio A, Ficorella C, Sidoni A, Bellezza G, Crinò L, Ludovini V, Baglivo S, Metro G, Chiari R. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Clin Transl Oncol. 2020 May; 22(5):708-716. PMID: 31332704.
    Citations: 2     Fields:    Translation:Humans
  48. Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer. 2020 01; 21(1):15-20. PMID: 31607443.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  49. Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 08 01; 37(22):1927-1934. PMID: 31206316.
    Citations: 59     Fields:    Translation:Humans
  50. Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019 10 20; 37(30):2738-2745. PMID: 31163011.
    Citations: 33     Fields:    Translation:Humans
  51. Ricciuti B, Genova C, Crinò L, Libra M, Leonardi GC. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019; 12:3171-3179. PMID: 31118670.
    Citations: 9     
  52. Xu H, Baidoo AAH, Su S, Ye J, Chen C, Xie Y, Bertolaccini L, Ismail M, Ricciuti B, Ng CSH, Flores RM, Li Y. A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. Transl Lung Cancer Res. 2019 Apr; 8(2):135-143. PMID: 31106124.
    Citations: 5     
  53. Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87. PMID: 30922388.
    Citations: 18     Fields:    Translation:Humans
  54. Ricciuti B. Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. J Thorac Dis. 2019 Mar; 11(Suppl 3):S249-S252. PMID: 30997189.
    Citations:    
  55. Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019 02 27; 7(1):57. PMID: 30813970.
    Citations: 79     Fields:    Translation:Humans
  56. Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, Chiari R. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. Clin Lung Cancer. 2019 05; 20(3):178-185.e2. PMID: 30910574.
    Citations: 11     Fields:    Translation:Humans
  57. Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist. 2019 06; 24(6):e327-e337. PMID: 30796151.
    Citations: 29     Fields:    Translation:Humans
  58. Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clin Lung Cancer. 2019 07; 20(4):237-247.e1. PMID: 30885550.
    Citations: 33     Fields:    Translation:Humans
  59. Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, Chiari R, Pirro M. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 2019 04; 196:105-116. PMID: 30521884.
    Citations: 27     Fields:    Translation:HumansAnimals
  60. Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019 Feb; 145(2):479-485. PMID: 30506406.
    Citations: 68     Fields:    Translation:Humans
  61. Ganjali S, Ricciuti B, Pirro M, Butler AE, Atkin SL, Banach M, Sahebkar A. High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. Trends Endocrinol Metab. 2019 01; 30(1):12-24. PMID: 30473465.
    Citations: 9     Fields:    Translation:Humans
  62. Ricciuti B, Marcomigni L, Metro G, Bellezza G, Caselli E, Baglivo S, Chiari R. Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. J Thorac Oncol. 2018 11; 13(11):e220-e222. PMID: 30368411.
    Citations: 1     Fields:    Translation:Humans
  63. Ludovini V, Ricciuti B, Tofanetti FR, Mencaroni C, Giannarelli D, Sidoni A, Reda MS, Siggillino A, Baglivo S, Crinò L, Bellezza G, Chiari R, Metro G. KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer. Mol Clin Oncol. 2018 Dec; 9(6):689-696. PMID: 30546903.
    Citations: 2     
  64. Baglivo S, Ricciuti B, Ludovini V, Metro G, Siggillino A, De Giglio A, Chiari R. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. J Thorac Oncol. 2018 08; 13(8):e145-e147. PMID: 30049377.
    Citations: 2     Fields:    Translation:Humans
  65. Pirro M, Ricciuti B, Rader DJ, Catapano AL, Sahebkar A, Banach M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog Lipid Res. 2018 07; 71:54-69. PMID: 29879431.
    Citations: 14     Fields:    Translation:HumansAnimals
  66. Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L, Chiari R. Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Med Oncol. 2018 Apr 17; 35(5):72. PMID: 29666949.
    Citations: 9     Fields:    Translation:HumansAnimals
  67. Ricciuti B, Baglivo S, Ludovini V, Sidoni A, Metro G, Brambilla M, Siggillino A, Reda MS, Rebonato A, Maiettini D, Chiari R. Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung Cancer. 2018 06; 120:70-74. PMID: 29748019.
    Citations: 3     Fields:    Translation:Humans
  68. Ricciuti B, Chiari R. First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. Transl Lung Cancer Res. 2018 Apr; 7(Suppl 2):S127-S130. PMID: 29782562.
    Citations: 2     
  69. Malapelle U, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G. Osimertinib. Recent Results Cancer Res. 2018; 211:257-276. PMID: 30069773.
    Citations: 7     Fields:    Translation:HumansAnimals
  70. Ricciuti B, Metro G, Brambilla M, Ludovini V, Baglivo S, Siggillino A, Prosperi E, Chiari R. Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. J Thorac Oncol. 2018 01; 13(1):e9-e12. PMID: 29258673.
    Citations: 4     Fields:    Translation:Humans
  71. Ricciuti B, Baglivo S, De Giglio A, Chiari R. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis. 2018 Jan-Dec; 12:1753466618808659. PMID: 30355049.
    Citations: 7     Fields:    Translation:Humans
  72. De Giglio A, Porreca R, Brambilla M, Metro G, Prosperi E, Bellezza G, Pirro M, Chiari R, Ricciuti B. Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? Thromb Res. 2018 03; 163:51-53. PMID: 29353684.
    Citations: 5     Fields:    Translation:Humans
  73. Ricciuti B, Foglietta J, Chiari R, Sahebkar A, Banach M, Bianconi V, Pirro M. Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. Med Oncol. 2017 Dec 04; 35(1):4. PMID: 29209837.
    Citations: 1     Fields:    Translation:HumansAnimals
  74. Ricciuti B, Foglietta J, Bianconi V, Sahebkar A, Pirro M. Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. Semin Cancer Biol. 2019 06; 56:87-99. PMID: 29128510.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  75. Bianconi V, Sahebkar A, Kovanen P, Bagaglia F, Ricciuti B, Calabrò P, Patti G, Pirro M. Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy. Pharmacol Ther. 2018 01; 181:156-168. PMID: 28827151.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  76. Baglivo S, Ludovini V, Sidoni A, Metro G, Ricciuti B, Siggillino A, Rebonato A, Messina S, Crinò L, Chiari R. Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clin Proc. 2017 08; 92(8):1304-1311. PMID: 28778263.
    Citations: 9     Fields:    Translation:Humans
  77. Ricciuti B, Metro G, Baglivo S, Colabrese D, Chiari R, Bennati C, Paglialunga L. Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. J Thorac Oncol. 2017 05; 12(5):e51-e55. PMID: 28434516.
    Citations: 2     Fields:    Translation:Humans
  78. Ricciuti B, Brambilla M, Metro G, Baglivo S, Matocci R, Pirro M, Chiari R. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Med Oncol. 2017 Jun; 34(6):105. PMID: 28444624.
    Citations: 13     Fields:    Translation:Humans
  79. Ricciuti B, Baglivo S, Paglialunga L, De Giglio A, Bellezza G, Chiari R, Crinò L, Metro G. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol. 2017 Jun; 9(6):387-404. PMID: 28607578.
    Citations: 11     
  80. Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R. The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opin Drug Saf. 2017 Jan; 16(1):101-109. PMID: 27910704.
    Citations: 2     Fields:    Translation:HumansAnimals
  81. Ricciuti B, Metro G, Leonardi GC, Sordo RD, Colella R, Puma F, Ceccarelli S, Potenza R, Rebonato A, Maiettini D, Crinò L, Chiari R. Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland. Tumori. 2016 Nov 11; 102(Suppl. 2). PMID: 27133228.
    Citations: 4     Fields:    Translation:Humans
  82. Ricciuti B, Leonardi GC, Ravaioli N, De Giglio A, Brambilla M, Prosperi E, Ribacchi F, Meacci M, Crinò L, Maiettini D, Chiari R, Metro G. Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. J Breast Cancer. 2016 Sep; 19(3):324-329. PMID: 27721883.
    Citations: 6     
  83. Paglialunga L, Salih Z, Ricciuti B, Califano R. Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open. 2016; 1(4):e000022. PMID: 27843619.
    Citations: 6     
  84. Ricciuti B, Chiari R, Chiarini P, Crinò L, Maiettini D, Ludovini V, Metro G. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Clin Drug Investig. 2016 Aug; 36(8):683-6. PMID: 27177916.
    Citations: 15     Fields:    Translation:Humans
  85. Bennati C, Paglialunga L, Ricciuti B, Metro G, Marcomigni L, Gili A, Crinò L. Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Manag. 2016 Jun; 5(2):79-90. PMID: 30643552.
    Citations: 1     
  86. Metro G, Lunardi G, Bennati C, Chiarini P, Sperduti I, Ricciuti B, Marcomigni L, Costa C, Crinò L, Floridi P, Gori S, Chiari R. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. J Neurooncol. 2016 09; 129(2):355-61. PMID: 27324494.
    Citations: 7     Fields:    Translation:Humans
  87. Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, Sidoni A, Mountzios G, Crinò L, Bellezza G, Rebonato A, Ferolla P, Toschi L. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer. 2016 May; 95:82-7. PMID: 27040856.
    Citations: 7     Fields:    Translation:Humans
  88. Ricciuti B, Mencaroni C, Paglialunga L, Paciullo F, Crinò L, Chiari R, Metro G. Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Med Oncol. 2016 Feb; 33(2):18. PMID: 26786153.
    Citations: 62     Fields:    Translation:Humans
  89. Ricciuti B, Rebonato A, Capodicasa E. Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking. BMJ Case Rep. 2015 Dec 14; 2015. PMID: 26667664.
    Citations: 1     Fields:    Translation:Humans
  90. Ricciuti B, Leonardi GC, Metro G, Grignani F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A, Zicari D, Crinò L. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Rev Respir Med. 2016; 10(1):53-68. PMID: 26714748.
    Citations: 14     Fields:    Translation:Humans
  91. Metro G, Chiari R, Ricciuti B, Rebonato A, Lupattelli M, Gori S, Bennati C, Castrioto C, Floridi P, Minotti V, Chiarini P, Crinò L. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opin Pharmacother. 2015; 16(17):2601-13. PMID: 26439599.
    Citations: 7     Fields:    Translation:Humans
  92. Ricciuti B, Leone MC, Metro G. Melanosis coli or ischaemic colitis? That is the question. BMJ Case Rep. 2015 Sep 04; 2015. PMID: 26341164.
    Citations:    Fields:    Translation:Humans
  93. Ricciuti B, Mecca C, Cenci M, Leonardi GC, Perrone L, Mencaroni C, Crinò L, Grignani F, Baglivo S, Chiari R, Sidoni A, Paglialunga L, Currà MF, Murano E, Minotti V, Metro G. miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. Ecancermedicalscience. 2015; 9:569. PMID: 26435742.
    Citations: 6     
  94. Metro G, Valtorta E, Siggillino A, Lauricella C, Cenci M, Ludovini V, Minenza E, Prosperi E, Ricciuti B, Rebonato A, Bassetti A, Crinò L. Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. Ecancermedicalscience. 2015; 9:559. PMID: 26284123.
    Citations: 4     
  95. Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015 Mar; 87(3):211-9. PMID: 25601484.
    Citations: 23     Fields:    Translation:Humans
  96. Ricciuti B, Mecca C, Crinò L, Baglivo S, Cenci M, Metro G. Non-coding RNAs in lung cancer. Oncoscience. 2014; 1(11):674-705. PMID: 25593996.
    Citations: 17     
  97. Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Clin Lung Cancer. 2014 Jan; 15(1):86-92. PMID: 24139827.
    Citations: 17     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ricciuti's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (158)
Explore
_
Co-Authors (39)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.